BioScience Health Innovations, Inc. (BHIC) stock
Close on Oct 16, 2026Market cap $79.22MP/E –Yield –
BioScience Health Innovations, Inc. grew revenue 7.8% to $4.49M over the twelve months to Jun 30, 2026. Operating income fell 164.5% to -$613.24K, moving the operating margin from 22.8% to -13.7%. At the latest close the market valued the company at $79.22M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $79.22M
- P/E ratio
- –
- Price to sales
- 17.64
- Price to book
- 43.17
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.49M
- Net income
- -$658.07K
- EPS, diluted
- -$0.06
- Book value per share
- $0.16
- Diluted shares
- 12M
Trading
- Previous close
- $6.78
- Open
- $6.78
- Day's range
- $6.78 – $6.78
- Volume
- 0
- Average volume (20 days)
- 1,861
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | BHIC | S&P 500 | Difference | BHIC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.6% | +1.5% | −6.1 pts | ||
| 3 months | +67.8% | +1.9% | +65.9 pts | ||
| Year to date | +69.5% | +12.8% | +56.7 pts | ||
| 1 year | +69.5% | +16.8% | +52.7 pts | ||
| 3 years | -87.0% | +81.5% | −168.5 pts | -49.3% | +22.0% |
| 5 years | -47.4% | +83.0% | −130.4 pts | -12.0% | +12.8% |
Six years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
About BioScience Health Innovations
Services-Computer Processing & Data Preparation
BioScience Health Innovations Inc., operating through its wholly owned subsidiary Best 365 Labs, Inc., is a health and wellness enterprise focused on mitochondrial health science, metabolic care, and advanced peptide delivery. The company develops and markets clinically tested natural products designed to support immune health and combat bacteria and viruses. Its core technology is the patent-pending Mineral Oxide Delivery System (MODS Max™) process, which enhances nutrient and peptide bioavailability across oral, sublingual, nasal, and topical formats. Offerings include formulations for hormonal optimization, such as its sublingual testosterone product NHTO/TPrime365, and NAD+ cellular health products. The company distributes its offerings directly to consumers via digital storefronts and through wholesale accounts and healthcare pharmacy partners.
Company profile, executives and historyBioScience Health Innovations stock: common questions
What is BioScience Health Innovations's stock price?
BHIC closed at $6.78 on Oct 16, 2026, up 0.00% on the day.
What is BioScience Health Innovations's market cap?
BioScience Health Innovations was worth $79.22M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is BHIC's P/E ratio?
BioScience Health Innovations lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.06), so it has no meaningful P/E ratio.
How much revenue does BioScience Health Innovations make?
BioScience Health Innovations reported revenue of $4.49M for the twelve months to Jun 30, 2026, up 7.8% from a year earlier.
Does BioScience Health Innovations pay a dividend?
No. BioScience Health Innovations has not paid a cash dividend over the last twelve months.
How has BHIC stock performed over the past year?
Including dividends, BHIC returned +69.5% over the past year, against +16.8% for the S&P 500.
Who are BioScience Health Innovations's competitors?
Companies most similar to BioScience Health Innovations by business, industry and size include MOVE, DTCX, KOAN, WORX, KWIK.
See a number that looks wrong?